Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 7/20 | 0.75 |
| ▸ | NCS1 | P62166 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ACP1 | P24666 | 2/20 | 0.57 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.57 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.57 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.57 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.57 |
| ▸ | SCD | O00767 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287798 | 0.86 | CSNK1D (1.00) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL5184333 | 0.83 | CSNK1D (0.67) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL17287819 | 0.83 | CSNK1D (0.67) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL27371534 | 0.80 | CSNK1D (0.70) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL4244535 | 0.80 | CSNK1D (0.73) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL25938107 | 0.77 | CSNK1D (0.69) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| Hydrochloric Acid SCHEMBL25333657 | 0.76 | CSNK1D (0.68) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL5070926 | 0.76 | POLB (0.76) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL11887784 | 0.76 | POLB (0.84) | CSNK1DNCS1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL230181 | 0.75 | GAA (0.71) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352082-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2015-12-10 | — | — | US | claimed |
| EP-2949651-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2015-12-02 | — | — | EP | claimed |
| EP-3348550-B1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2019-04-24 | — | — | EP | disclosed |
| EP-3348550-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2018-07-18 | — | — | EP | disclosed |
| US-9592224-B2 | Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases | DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2017-03-14 | — | — | US | disclosed |
| US-20150352082-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2015-12-10 | — | — | US | disclosed |
| EP-2949651-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2015-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352082-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CSNK1A1, CRY1, CSNK1G1 | CSNK1D 13/4885NCS1 114/4885SMN1; SMN2 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.